Partnering with TSRL

Supporting Translational Research through Strategic Collaboration

TSRL is the preclinical CRO that helps bridge the gap between discovery and development. With a science-first mindset, we partner with academic teams, research institutions, and entrepreneurs to advance early-stage therapeutics with commercial potential. By combining hands-on drug development expertise with deep experience in non-dilutive funding, we offer a practical path forward for promising technologies that need support to reach the clinic.

 

The Opportunity

Academic innovation continues to drive the search for new therapies. Many pharmaceutical companies now look to universities and research hospitals for their next breakthroughs. In parallel, the National Institutes of Health (NIH) provides nearly $30 billion in annual non-dilutive funding to help turn basic science into real-world treatments. 

These forces create powerful opportunities for academic founders to move discoveries forward.

 

The Challenge

Despite growing interest in early-stage assets, investors often wait for more advanced development milestones. This shift leaves many projects without the resources or commercialization strategies needed to reach the next phase. 

As a result, potentially valuable treatments may stall in the lab before they can demonstrate their impact.

 

Bridging the “Valley of Death”

TSRL partners with academic and start-up innovators to help close the translational gap between research and clinical readiness. We support funded collaborations through grant co-development, preclinical services, and business planning. Our tenured team includes pharmaceutical scientists, commercialization experts, and proposal writers who know how to build a compelling case for support. 

Together, we work to turn strong ideas into viable therapeutic programs.

 

Why Partner with TSRL? 

Collaborators benefit from a tailored development path built around project milestones and TSRL’s preclinical services.

  • Deep hands-on drug development leadership and project planning since 1986

  • On-site wet lab space and AAALAC-accredited animal facilities in Ann Arbor, Michigan

  • Analytical chemistry, formulation, PK/PD, and exploratory tox support

  • Business development and commercialization strategy

We understand that every project is shaped by the characteristics of the compound and the shared goal of reaching an IND.

 

Non-Dilutive Funding Expertise

TSRL’s track record includes more than $21 million in secured awards, with a 40% success rate over the last decade! We support, and help partners gain, a wide variety of funding mechanisms, including:

  • SBIR (Phase I, II, III)

  • Cooperative grants (e.g., U44)

  • RFAs (e.g., RO1 biodefense)

Success often comes from TSRL scientists and grant experts who work to strengthen partner applications with strong research and a compelling commercialization plan. We focus on high-quality data, clear project management, and well-designed studies that make applications more competitive, and we can serve as either a co-investigator or principal investigator where appropriate.

 

Expand Your Team with Preclinical Experts

TSRL offers far more than the average advisory team, providing practical, science-driven support to de-risk your program and move it forward. Our facility includes 5,000 sq. ft of wet lab space, formulation suites, and in vitro/in vivo testing capabilities. We generate the data that builds confidence in your compound, and help translate that into progress with reviewers, partners, and future funders.

Partner with TSRL today to accelerate breakthroughs with hands-on science, non-dilutive funding, and the support you need to move from promise to proof.

 

Ready to Collaborate?

Connect with a TSRL scientist to learn how we can support your goals with strategic, science-driven solutions by filling out this form.